LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System

Reuters

2025/11/06

LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System

LifeTech Scientific Corporation has announced that its G-Branch™ Thoracoabdominal Artery Stent Graft System has received official registration approval from the China National Medical Products Administration (NMPA). This approval follows the earlier launch of the company's Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, further expanding LifeTech's portfolio in peripheral vascular intervention. With this milestone, LifeTech becomes one of the first innovative companies to offer integrated endovascular aortic repair solutions globally. The company plans to continue advancing and commercializing new medical device products to address urgent clinical needs. No grant or funding from multiple organizations was mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581709892"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581709892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581709892?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581709892","market":"us","top_or_hot":-1,"title":"LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LifeTech Scientific Corporation has announced that its G-Branch™ Thoracoabdominal Artery Stent Graft System has received official registration approval from the <a href=\"https://laohu8.com/S/688128\">China National</a> Medical Products Administration (NMPA). This approval follows the earlier launch of the company's Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, further expanding LifeTech's portfolio in peripheral vascular intervention. With this milestone, LifeTech becomes one of the first innovative companies to offer integrated endovascular aortic repair solutions globally. The company plans to continue advancing and commercializing new medical device products to address urgent clinical needs. No grant or funding from multiple organizations was mentioned in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LifeTech Scientific Corporation has announced that its G-Branch™ Thoracoabdominal Artery Stent Graft System has received official registration approval from the <a href=\"https://laohu8.com/S/688128\">China National</a> Medical Products Administration (NMPA). This approval follows the earlier launch of the company's Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, further expanding LifeTech's portfolio in peripheral vascular intervention. With this milestone, LifeTech becomes one of the first innovative companies to offer integrated endovascular aortic repair solutions globally. The company plans to continue advancing and commercializing new medical device products to address urgent clinical needs. No grant or funding from multiple organizations was mentioned in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5dyFKk:1","article_id":"2581709892","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581709892","pubTimestamp":1762433436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LifeTech Scientific Corporation has announced that its G-Branch Thoracoabdominal Artery Stent Graft System has received official registration approval from the China National Medical Products Administration . This approval follows the earlier launch of the company's Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, further expanding LifeTech's portfolio in peripheral vascular intervention. With this milestone, LifeTech becomes one of the first innovative companies to offer integrated endovascular aortic repair solutions globally. The company plans to continue advancing and commercializing new medical device products to address urgent clinical needs. No grant or funding from multiple organizations was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","BK1583":"高瓴概念","01302":"先健科技","BK1100":"医疗保健设备"},"translate_title":"先健科技G分支胸腹动脉覆膜支架系统获中国国家药监局批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01302":0.9},"content_text":"LifeTech Scientific Wins China NMPA Approval for G-Branch Thoracoabdominal Artery Stent Graft System\n    \n\n        LifeTech Scientific Corporation has announced that its G-Branch™ Thoracoabdominal Artery Stent Graft System has received official registration approval from the China National Medical Products Administration (NMPA). This approval follows the earlier launch of the company's Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, further expanding LifeTech's portfolio in peripheral vascular intervention. With this milestone, LifeTech becomes one of the first innovative companies to offer integrated endovascular aortic repair solutions globally. The company plans to continue advancing and commercializing new medical device products to address urgent clinical needs. No grant or funding from multiple organizations was mentioned in the announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}